Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis

Risultato della ricerca: Articlepeer review

6 Citazioni (Scopus)

Abstract

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.
Lingua originaleEnglish
pagine (da-a)S15-S20
Numero di pagine6
RivistaDermatologic Therapy
Volume21
Stato di pubblicazionePublished - 2008

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Entra nei temi di ricerca di 'Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis'. Insieme formano una fingerprint unica.

Cita questo